Candin for the Treatment of Common Warts

* At least 3, but not more than 20 common warts (Verruca vulgaris)

* Willing to agree to use adequate contraception methods during the study

* Systemic or localized diseases, conditions, or medications that could interfere with the assessment of safety or efficacy or that compromise immune function

* Candin delayed type hypersensitivity reaction test wheal sized < 5 mm or > 25 mm at the Baseline Visit

* History of keloid formation

* Prior treatment of common warts with liquid nitrogen, carbon dioxide, electrodesiccation, laser, surgery, salicylic acid, etc., that, in the Investigator's opinion, does not exhibit complete healing from the treatment

* Treatment with immunotherapy (e.g., diphenylcyclopropenone [DPCP], dinitrochlorobenzene [DNCB], or other), imiquimod, 5-fluorouracil, bleomycin, or podophyllin within 12 weeks of the Baseline Visit or during the study

* Prior treatment with Candida albicans within 12 weeks of the Baseline Visit or during the study

* Systemic treatment with an immunosuppressive drug during the study or in the 6 months or 5 half lives prior to the Baseline Visit or during the study (e.g., azathioprine, 6 mercaptopurine, methotrexate, infliximab, adalimumab, etanercept, systemic steroids [topical or inhaled steroids are acceptable]).

* Use of cantharidin or an investigational agent or device within the 30 days prior to the Baseline Visit or during the study